Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Animal studies in vivo indicate that leptin treatment in extremely leptin-sensitive ob/ ob mice reduces body weight exclusively by reducing fat mass and that it increases muscle mass by downregulating myostatin expression. Data from human trials are limited. Therefore, we aimed at characterizing the effects of leptin administration on fat mass, lean body mass, and circulating regulators of muscle growth in hypoleptinemic and presumably leptin-sensitive human subjects. In an open-label, single-arm trial, seven lean, strenuously exercising, amenorrheic women with low leptin concentrations (≤5 ng/ml) were given recombinant methionyl human leptin (metreleptin; 0.08 mg·kg−1·day−1) for 10 wk. In a separate randomized, double-blind, placebo-controlled trial, seven women were given metreleptin (initial dose: 0.08 mg·kg−1·day−1 for 3 mo, increased thereafter to 0.12 mg·kg−1·day−1 if menstruation did not occur), and six were given placebo for 9 mo. Metreleptin significantly reduced total body fat by an average of 18.6% after 10 wk ( P < 0.001) in the single-arm trial and by 19.5% after 9 mo (placebo subtracted; P for interaction = 0.025, P for metreleptin = 0.004) in the placebo-controlled trial. There were no significant changes in lean body mass ( P ≥ 0.33) or in serum concentrations of myostatin ( P ≥ 0.35), follistatin ( P ≥ 0.30), and activin A ( P ≥ 0.20) whether in the 10-wk trial or the 9-mo trial. We conclude that metreleptin administration in lean hypoleptinemic women reduces fat mass exclusively and does not affect lean body mass or the myostatin-follistatin-activin axis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Farooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S. A., Perna, F., Fontana, S., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215693 · Cited by 1,105
Recombinant human leptin in women with hypothalamic amenorrhea
Welt, C. K., Chan, J. L., Bullen, J., Murphy, R., Smith, P., DePaoli, A. M., Karalis, A., & Mantzoros, C. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040388 · Cited by 908
Self-citationREGULATION OF MUSCLE MASS BY MYOSTATIN
Lee, S.-J. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.135836 · Cited by 819
Gonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ezzat, S., Shen, R., Lalani, R., Asa, S., Mamita, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14938 · Cited by 571 · cited 3×
“Myostatin protein is produced by skeletal muscle, circulates in blood (11), and acts to limit muscle growth by signaling through the activin receptors (18, 21).”
BackgroundSuppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505 · cited 1×
“Genetic loss of myostatin function is associated with muscle hypertrophy in mice and humans (21, 29) in an apparently dose-dependent manner (22), whereas myostatin excess is associated with muscle cachexia (34).”
BackgroundControl of the size of the human muscle mass
Rennie, M. J., Wackerhage, H., Spangenburg, E. E., & Booth, F. W. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.052102.134444 · Cited by 399 · cited 1×
“Regulation of muscle mass in humans is complex and depends on the balance between protein degradation and protein synthesis, which in turn is affected by several nutritional, exercise, and hormonal factors (27).”
BackgroundGibson, W. T., Farooqi, I. S., Moreau, M., DePaoli, A. M., Lawrence, E., O’Rahilly, S., & Trussell, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0376 · Cited by 275 · cited 1×
“Inconsistent results have been reported in young patients with congenital leptin deficiency, since some studies indicate a decrease (10) and others an increase (8) in lean body mass in response to leptin treatment.”
ResultRegulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273 · cited 4×
“Activin A is probably another ligand regulated by follistatin that functions with myostatin to limit muscle mass (19).”
BackgroundInfluentialMoon, H.-S., Matarese, G., Brennan, A. M., Chamberland, J. P., Liu, X., Fiorenza, C. G., Mylvaganam, G. H., Abanni, L., Carbone, F., Williams, C. J., et al. (2011) · Diabetes · doi:10.2337/db10-1791 · Cited by 151
Cited by
Leptin in Human Physiology and Pathophysiology
Mantzoros, C. S., Magkos, F., Brinkoetter, M., Sienkiewicz, E., Dardeno, T. A., Kim, S.-Y., Hamnvik, O.-P. R., & Koniaris, A. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2011 · Cited by 593
Self-citationMichalakis, K., Mintziori, G., Kaprara, A., Tarlatzis, B. C., & Goulis, D. G. (2013) · Metabolism · doi:10.1016/j.metabol.2012.08.012 · Cited by 321
“The classic belief that leptin is the signal to stop eating and reduce weight is valid; still, more important is the role of leptin in adapting the organism in the state of reduced energy intake and reduced body fat stores [104–110].”
BackgroundLeptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
Moon, H.-S., Dalamaga, M., Kim, S.-Y., Polyzos, S. A., Hamnvik, O.-P., Magkos, F., Paruthi, J., & Mantzoros, C. S. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1053 · Cited by 258
Self-citationFedewa, M. V., Hathaway, E. D., Ward-Ritacco, C. L., Williams, T. D., & Dobbs, W. C. (2018) · Sports Medicine · doi:10.1007/s40279-018-0897-1 · Cited by 135
Role of the Cytokine-like Hormone Leptin in Muscle-bone Crosstalk with Aging
Hamrick, M. W. (2017) · Journal of Bone Metabolism · doi:10.11005/jbm.2017.24.1.1 · Cited by 77
“Recombinant human leptin (rhLep) has shown potential for increasing IGF-1 and markers of bone formation in women with hypothalamic amenorrhea,[67] although other studies indicate that the effects of rhLep on lean mass may be more modest.[68] Resistance exercise can improve muscle strength and power in the elderly[69,7…”
Result
Metadata
- Authors
- Brinkoetter, M., Magkos, F., Vamvini, M., & Mantzoros, C. S.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2011-07
- Volume
- 301
- Issue
- 1
- Pages
- E99-E104
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2164108119
- Cited by
- 28
- References
- 12
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women. https://app.cochat.ai/papers/10.1152/ajpendo.00146.2011
- The paper
- Brinkoetter, M., Magkos, F., Vamvini, M., & Mantzoros, C. S. (2011). Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00146.2011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.